Research Article
Assessment of Trimetazidine Treatment in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
Table 4
Repeated laboratory data collected in the hospital.
| | TMZ group (n = 200) | Control group (n = 201) | value |
| CK on day 2 (U/L) | 838 ± 732 | 1046 ± 1048 | 0.022 | CKMB on day 2 (U/L) | 86 ± 71 | 106 ± 104 | 0.022 | CRP on day 2 (pg/ml) | 101.5 ± 193.5 | 121.1 ± 225.9 | 0.554 | TNF-α on day 2 (pg/ml) | 51.3 ± 83.4 | 51.8 ± 87.4 | 0.968 | cTNI on day 2 (ng/ml) | 14.3 ± 14.5 | 17.0 ± 17.9 | 0.092 | cTNI on day 6 (ng/ml) | 3.5 ± 3.5 | 4.7- ± 4.9 | 0.003 | ALT on day 6 (U/L) | 33.8 ± 25.0 | 43.6 ± 32.7 | 0.001 | AST on day 6 (U/L) | 42.1 ± 26.8 | 62.8 ± 54.8 | <0.001 | Cr on day 6 (μmo l/L) | 80.7 ± 26.3 | 82.2 ± 28.0 | 0.583 | Urea on day 6 (mmol/L) | 6.3 ± 4.8 | 6.5 ± 11.6 | 0.843 | Glucose on day 6 (mmol/L) | 6.0 ± 1.7 | 6.4 ± 1.9 | 0.011 |
|
|
All comparisons were two-tailed, and was considered statistically significant. |